logo
Book a meeting
LadRx Corporation

Lad Rx Corporation

Biotechnology, San Vicente BLVD Ste 650, Los Angeles, , 90049, California, 11726, United States, 1-10 Employees

ladrxcorp.com

  • LinkedIn

phone no Phone Number: 31********

Who is LADRX CORPORATION

LadRx Corporation (OTCQB: LADX) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer. LadRxs most recent ...

Read More

lock icon Get Full Access
map
  • 11726 San Vicente BLVD Ste 650, Los Angeles, California, 90049, United States Headquarters: 11726 San Vicente BLVD Ste 650, Los Angeles, California, 90049, United States
  • 1985 Date Founded: 1985
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: $25 Million to $50 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2836 | NAICS Code: 325414 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from LADRX CORPORATION

LadRx Corporation Org Chart and Mapping

Employees
Anne Reims

Anne Reims

Admin Asst

See Full Org Chart arrow
email-formate-icon
View Email Formats for LadRx Corporation
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding LadRx Corporation

Answer: LadRx Corporation's headquarters are located at San Vicente BLVD Ste 650, Los Angeles, , 90049, California, 11726, United States

Answer: LadRx Corporation's phone number is 31********

Answer: LadRx Corporation's official website is https://ladrxcorp.com

Answer: LadRx Corporation's revenue is $25 Million to $50 Million

Answer: LadRx Corporation's SIC: 2836

Answer: LadRx Corporation's NAICS: 325414

Answer: LadRx Corporation has 1-10 employees

Answer: LadRx Corporation is in Biotechnology

Answer: LadRx Corporation contact info: Phone number: 31******** Website: https://ladrxcorp.com

Answer: LadRx Corporation (OTCQB: LADX) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer. LadRxs most recent advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to ImmunityBio, Inc. In addition, LadRxs drug candidate, arimoclomol, was sold to Orphazyme A/S (now Zevra Therapeutics) in exchange for milestone payments and royalties. Zevra is developing arimoclomol and is currently focused on Niemann-Pick disease Type C (NPC).

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access